Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

in Europe for maintenance treatment of adult patients with schizophrenia who are sufficiently stabilized during acute treatment with oral Zyprexa. In the U.S., the company has submitted a complete response to the FDA's not approvable letter and is currently awaiting the FDA's final review.

-- Gamma Secretase Inhibitor - In March 2008, the company began its first pivotal trial in Alzheimer's disease for the gamma secretase inhibitor, a small molecule designed to reduce the levels of the amyloid beta peptide in the brain. The trial, called IDENTITY, is actively enrolling and is ahead of schedule. A second pivotal trial, IDENTITY 2, was started in September 2008 and is also enrolling at a better-than-expected rate. Approximately 400 subjects have now been randomized in the two studies.

-- A-beta Antibody - A monoclonal antibody, the company's A-beta antibody offers the potential for slowing down the progression of Alzheimer's disease. It is expected to enter Phase III in 2009.

-- Enzastaurin - A Phase III clinical trial is currently under way for the use of enzastaurin as a maintenance therapy for diffuse large B-cell lymphoma. Because events are occurring at a slower rate than projected, the company is considering expanding enrollment and extending the trial. The company now expects U.S. regulatory submission to occur in mid-2013.

-- Teplizumab - The company continues to collaborate with its partner, MacroGenics Inc., on teplizumab, which is currently being studied in a pivotal Phase II/III clinical trial for Type 1 diabetes.

-- Dirucotide (MBP8298) - Along with its partner, BioMS, the company is studying dirucotide for the treatment of several types of multiple sclerosis (MS). There are two Phase III clinical trials ongoing targeting secondary progressive MS, one in Europe and Canada, and the other in the U.S. There is also a Phase II clinical trial underway in Europe for rel
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... have developed a unique nanoscale device that for ... The discovery could have major implications for creating ... and communication. , The research paper by University ... Mo Li and his graduate student Huan Li ... the October issue of Nature Nanotechnology . ...
(Date:9/22/2014)... Rhinebeck, NY (PRWEB) September 22, 2014 ... commitment helping those in pain end their suffering, restoring ... sustainable healthcare model. This is only possible because of ... relief and healing cream technology a reality. , ... in Rhinebeck, NY, by Lou Paradise (president, chief of ...
(Date:9/22/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCBB:GNBT) today announced ... University Health Network (UHN) pursuant to which UHN,s ... spearhead the Company,s buccal insulin refinement project.  The ... insulin bioavailability of Generex Oral-lyn™, the Company,s proprietary ...
(Date:9/22/2014)... September 22, 2014 METTLER TOLEDO ... and pallet measuring device CNS110 ScanTape™ . ... data entry, offering greater ease and accuracy for ... result can significantly enhance productivity—an important benefit for ... processing volume equals profits. , Usable at ...
Breaking Biology Technology:Engineers show light can play seesaw at the nanoscale 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4ScanTape™ Handheld Dimensioner Increases Processing Volume 2
... - Immunocytokine Combining Peregrine,s Anti-PS Antibodies and IL-2,Protected 80% of Animals From a Lethal Challenge ... ... at International Conference on Vascular Targeted, Therapies in Oncology Further Supports a Second ... ...
... Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH), ... and,commercializing targeted cancer therapeutics, announced today that it ... 11, 2007 at 2:00 p.m.,Pacific Time at the ... San Francisco.,Daniel Greenleaf, VioQuest,s president and CEO, is ...
... Corporation,(Nasdaq: IOMI ) today announced that Stanley C. ... at the Natixis,Bleichroeder Hidden Gems Conference in New York ... at 2:45 p.m. Eastern Time in the in,Union Square ... live audio webcast or the subsequent archived recording,log on ...
Cached Biology Technology:New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 2New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 3New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform 4VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3
(Date:9/21/2014)... CAMBRIDGE, MA -- In recent years, new strains of ... antibiotics. Each year, these superbugs, including drug-resistant forms of ... nationwide, and kill at least 23,000. Despite the urgent ... new classes of antibiotics in the past decade. , ... on these superbugs. Using a gene-editing system that can ...
(Date:9/19/2014)... dinosaurs a newly discovered hadrosaur with a ... Rhinorex condrupus by paleontologists from North ... in what is now Utah approximately 75 million ... Rhinorex, which translates roughly into "King Nose," was ... Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4New hadrosaur noses into spotlight 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3
... breath may indicate how susceptible they are to weight gain, ... Endocrine Society,s Journal of Clinical Endocrinology & Metabolism ... hydrogen and methane gases are more likely to have a ... to the findings. The combination of the two gases signals ...
... the early 1940s, California fishermen hauled in a historic bounty of ... "Cannery Row" novel. But by the end of the decade the ... all go? According to a new study led by scientists at ... the sardine mystery are a dynamic and interconnected moving target. ...
... March 25, 2013 Until now most experimental vaccines ... effectiveness. But a new vaccine has proven highly effective against ... is also effective against the H9 subtype of avian influenza. ... Journal of Virology . The strength of ...
Cached Biology News:Microorganisms detected via breath test linked to body mass, fat accumulation 2Predictions of climate impacts on fisheries can be a mirage 2Cleverly designed vaccine blocks H5 avian influenza in models 2
...
... SpliceArray service, ExonHit can design custom microarrays ... your gene list. Proprietary algorithms are ... microarray probes from high quality, spliced cDNAs ... event contained in a custom SpliceArray is ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
Biology Products: